In a report released today, Joseph Pantginis from H.C. Wainwright initiated coverage with a Buy rating on Alpine Immune Sciences (ALPN) and a price target of $21.00. The company’s shares closed last Friday at $14.57, close to its 52-week high of $15.00.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 34.6% and a 63.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.
Currently, the analyst consensus on Alpine Immune Sciences is a Moderate Buy with an average price target of $20.00.
See today’s analyst top recommended stocks >>
Alpine Immune Sciences’ market cap is currently $346.8M and has a P/E ratio of -10.10. The company has a Price to Book ratio of 5.14.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALPN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.
